Document Detail

Anti-angiogenic therapy in high-grade glioma (treatment and toxicity).
MedLine Citation:
PMID:  23417315     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Malignant gliomas continue to have a very poor prognosis and treatment responses at recurrence are very limited. Though anti-angiogenic therapy has not yet been shown to extend overall survival in this patient population, there is likely substantial benefit to reducing vasogenic edema, allowing for temporary improvement in neurologic function, and minimizing the side effects of prolonged corticosteroid use. A trial of bevacizumab should be considered in those with worsening vasogenic cerebral edema such as seen in recurrent malignant gliomas, radiation necrosis, or progressive brain metastases. However, not all patients respond to anti-angiogenic treatment and if no radiographic or clinical responses are seen, then patients are not likely to benefit from further infusions. Though it is commonly well tolerated, some side effects, while rare, may be life threatening, and should be discussed with patients and their families. These discussions should also outline the goals of initiating therapy and when treatment should be stopped.
Jennie Taylor; Elizabeth R Gerstner
Related Documents :
1532145 - Surgical treatment of cancer of the cervix.
11049235 - A clinicopathological study of postoperatively upgraded early squamous-cell carcinoma o...
16600755 - Pelvic organ support and prevalence by pelvic organ prolapse-quantification (pop-q) in ...
21181475 - Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
22836055 - Association of clinical response and long-term outcome among patients with biopsied orb...
23043575 - Outcomes following treatment for patients with cranial nerve involvement from nasophary...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in neurology     Volume:  15     ISSN:  1092-8480     ISO Abbreviation:  Curr Treat Options Neurol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-13     Completed Date:  2013-05-14     Revised Date:  2014-07-02    
Medline Journal Info:
Nlm Unique ID:  9815940     Medline TA:  Curr Treat Options Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  328-37     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support
R01 CA129371/CA/NCI NIH HHS; U01 CA154601/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bioanalysis: heri, hodie, cras.
Next Document:  Reevaluation of T(2)-weighted fast field echo (T2FFE): application to rapid volumetric black-blood i...